Liikkanen Sammeli, Sinkkonen Janne, Suorsa Joni, Kaasinen Valtteri, Pekkonen Eero, Kärppä Mikko, Scheperjans Filip, Huttunen Teppo, Sarapohja Toni, Pesonen Ullamari, Kuoppamäki Mikko, Keränen Tapani
Orion Corporation, Orion Pharma, R&D, Espoo Finland.
DRDP, Institute of Biomedicine, University of Turku, Turku Finland.
PLOS Digit Health. 2023 Apr 7;2(4):e0000225. doi: 10.1371/journal.pdig.0000225. eCollection 2023 Apr.
In the quantification of symptoms of Parkinson's disease (PD), healthcare professional assessments, patient reported outcomes (PRO), and medical device grade wearables are currently used. Recently, also commercially available smartphones and wearable devices have been actively researched in the detection of PD symptoms. The continuous, longitudinal, and automated detection of motor and especially non-motor symptoms with these devices is still a challenge that requires more research. The data collected from everyday life can be noisy and frequently contains artefacts, and novel detection methods and algorithms are therefore needed. 42 PD patients and 23 control subjects were monitored with Garmin Vivosmart 4 wearable device and asked to fill a symptom and medication diary with a mobile application, at home, for about four weeks. Subsequent analyses are based on continuous accelerometer data from the device. Accelerometer data from the Levodopa Response Study (MJFFd) were reanalyzed, with symptoms quantified with linear spectral models trained on expert evaluations present in the data. Variational autoencoders (VAE) were trained on both our study accelerometer data and on MJFFd to detect movement states (e.g., walking, standing). A total of 7590 self-reported symptoms were recorded during the study. 88.9% (32/36) of PD patients, 80.0% (4/5) of DBS PD patients and 95.5% (21/22) of control subjects reported that using the wearable device was very easy or easy. Recording a symptom at the time of the event was assessed as very easy or easy by 70.1% (29/41) of subjects with PD. Aggregated spectrograms of the collected accelerometer data show relative attenuation of low (<5Hz) frequencies in patients. Similar spectral patterns also separate symptom periods from immediately adjacent non-symptomatic periods. Discriminative power of linear models to separate symptoms from adjacent periods is weak, but aggregates show partial separability of patients vs. controls. The analysis reveals differential symptom detectability across movement tasks, motivating the third part of the study. VAEs trained on either dataset produced embedding from which movement states in MJFFd could be predicted. A VAE model was able to detect the movement states. Thus, a pre-detection of these states with a VAE from accelerometer data with good S/N ratio, and subsequent quantification of PD symptoms is a feasible strategy. The usability of the data collection method is important to enable the collection of self-reported symptom data by PD patients. Finally, the usability of the data collection method is important to enable the collection of self-reported symptom data by PD patients.
在帕金森病(PD)症状的量化方面,目前采用医疗保健专业人员评估、患者报告结局(PRO)以及医疗设备级可穿戴设备。最近,市售智能手机和可穿戴设备在PD症状检测方面也得到了积极研究。利用这些设备持续、纵向且自动地检测运动症状尤其是非运动症状,仍然是一项需要更多研究的挑战。从日常生活中收集的数据可能存在噪声且经常包含伪迹,因此需要新颖的检测方法和算法。使用佳明Vivosmart 4可穿戴设备对42名PD患者和23名对照受试者进行了监测,并要求他们在家中使用移动应用程序填写症状和用药日记,为期约四周。后续分析基于该设备的连续加速度计数据。对左旋多巴反应研究(MJFFd)的加速度计数据进行了重新分析,使用基于数据中专家评估训练的线性谱模型对症状进行量化。在我们的研究加速度计数据和MJFFd数据上训练变分自编码器(VAE)以检测运动状态(例如行走、站立)。研究期间共记录了7590条自我报告的症状。88.9%(32/36)的PD患者、80.0%(4/5)的接受脑深部电刺激(DBS)治疗的PD患者以及95.5%(21/22)的对照受试者表示使用可穿戴设备非常容易或容易。70.1%(29/41)的PD患者认为在事件发生时记录症状非常容易或容易。收集到的加速度计数据的聚合频谱图显示患者中低频(<5Hz)相对衰减。类似的频谱模式也能将症状期与紧邻的无症状期区分开来。线性模型区分症状期与相邻期的能力较弱,但汇总数据显示患者与对照之间存在部分可分离性。分析揭示了不同运动任务中症状检测能力的差异,这推动了研究的第三部分。在任一数据集上训练的VAE生成了嵌入,据此可以预测MJFFd中的运动状态。一个VAE模型能够检测运动状态。因此,利用信噪比良好的加速度计数据通过VAE对这些状态进行预检测,随后对PD症状进行量化是一种可行的策略。数据收集方法的可用性对于PD患者能够收集自我报告的症状数据非常重要。最后,数据收集方法的可用性对于PD患者能够收集自我报告的症状数据非常重要。